Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration

Krystyna, Annika; Safi, Tarang; Briggs, William M.; Schwalb, Murray David

doi:10.1590/s1677-55382011000200009

Cited by 16 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, if the magnitude of PSA change is greater in middle‐ and older‐aged men than in younger men, as might be expected based on their likely greater degree of preexisting epithelial cell disruption and amount of PSA secreted, then these larger possible rises might be sufficient to influence both screening and biopsy decisions, and thus might be worth pursuing in future research. Additionally, whether or not noninfectious, inflammatory conditions, such as inflammatory bowel disease, influence serum PSA levels might also be of interest, but these have been examined in only a few small studies of hepatitis and periodontitis . We could not address this question in this study because our original data request was limited to infectious disease and genitourinary ICD‐9‐CM codes consistent with our original hypothesis, and because our de‐identified data can no longer be linked to the master DoDSR file.…”

Section: Discussionmentioning

confidence: 99%

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

et al. 2016

View full text Add to dashboard Cite

Although Epstein-Barr virus has been detected in prostate tissue, no associations have been observed with prostate cancer in the few studies conducted to date. One possible reason for these null findings may be use of cumulative exposure measures that do not inform the timing of infection, i.e., childhood versus adolescence/early adulthood when infection is more likely to manifest as infectious mononucleosis (IM). We sought to determine the influence of young adult-onset IM on the prostate by measuring prostate-specific antigen (PSA) as a marker of prostate inflammation/damage among U.S. military members. We defined IM cases as men diagnosed with IM from 1998 to 2003 (n 5 55) and controls as men without an IM diagnosis (n 5 255). We selected two archived serum specimens for each participant, the first collected after diagnosis for cases and one randomly selected from 1998 to 2003 for controls (index), as well as the preceding specimen (preindex). PSA was measured in each specimen. To explore the specificity of our findings for prostate as opposed to systemic inflammation, we performed a post hoc comparison of other infectious disease cases without genitourinary involvement (n 5 90) and controls (n 5 220). We found that IM cases were more likely to have a large PSA rise than controls (20 ng/mL: 19.7% versus 8.8%, p 5 0.027; 40% rise: 25.7% versus 9.4%, p 5 0.0021), as were other infectious disease cases (25.7% versus 14.0%, p 5 0.020; 27.7% versus 18.0%, p 5 0.092). These findings suggest that, in addition to rising because of prostate infection, PSA may also rise because of systemic inflammation, which could have implications for PSA interpretation in older men.

show abstract

Section: Discussionmentioning

confidence: 99%

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although hepatocellular carcinoma is the cancer most commonly associated with HCV, it has been found that several other malignancies are more common in those with CHC compared to the general population. Prostate cancer has been noted to correlate with detection of hepatitis C antibody [ 37 ]. In a study of Japanese patients, both oral and other digestive tract cancers were shown to correlate with HCV infection [ 38 ].…”

Section: Malignanciesmentioning

confidence: 99%

Hepatitis C virus as a systemic disease: reaching beyond the liver

et al. 2015

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) is associated with multiple extrahepatic manifestations that may impact infected patients. The mechanisms through which these develop include those which are immunological, in which the chronic persistence of virus leads to the circulation of immune complexes (mixed cryoglobulinemia) and other autoimmune phenomena, and those which are virological and related to the extrahepatic tropism of the virus to other tissues. It is estimated that 40–74 % of patients with CHC may develop at least one extrahepatic manifestation during the course of the disease. Extrahepatic syndromes may represent the first signal of hepatitis C infection in some patients. CHC is associated with a four-fold increased risk of insulin resistance and type 2 diabetes mellitus; with cardiovascular disease in 17–37 % of patients; and with increased risk for cerebrovascular deaths, with a biological gradient of cerebrovascular mortality correlating with an increasing serum viral load. CHC is also associated with lymphoproliferative disorders, particularly non-Hodgkin B-cell lymphoma. The kidney is involved in 35–60 % of patients with CHC-associated mixed cryoglobulinemia. The prevalent type of glomerulonephritis associated with mixed cryoglobulinemia is membranoproliferative glomerulonephritis. In 30 % of cases, renal involvement begins with a nephritis syndrome and acute renal failure, while in 55 % there is only mild hematuria, microalbuminuria, proteinuria and renal insufficiency. CHC is also associated with cognitive impairment, especially in memory and concentration. Thus, extrahepatic CHC manifestations involve multiple organ systems outside the liver linked to a variety of comorbidities which may lead to significantly increased mortality from non-liver-related events.

show abstract

“…Although our research continues to suggest increased odds of prostate cancer with hepatitis C antibody detection, our data concerning HIV and prostate cancer odds remain indeterminate 1 . We are currently investigating this.…”

Section: Discussionmentioning

confidence: 79%

“…The initial goals of database creation were to establish risks, benefits and selection criteria for transrectal prostate biopsy. In our search for risk factors for prostate cancer, our previous research revealed an association between hepatitis C antibody and prostate cancer during preliminary analysis for prostate cancer risk factors [1]. As the database expanded we collected more information and describe our findings in this report.…”

Section: Introductionmentioning

confidence: 94%

Hepatitis C antibody testing in African American and Hispanic men in New York City with prostate biopsy

Krystyna¹,

Kumari²,

Tenney³

et al. 2013

Oncol Discov

Self Cite

View full text Add to dashboard Cite

Background: An analysis of the Prostate Cancer Database Project previously identified an association between hepatitis C antibody testing and prostate cancer (Pca). Methods: The records of 864 African American (AA) and Hispanic men from January 1, 2000, thru July 31, 2011 with both prostate biopsy and hepatitis C antibody testing were examined. Chi-squared tests, T-tests of difference and logistic regression models were used to interpret data. A skill plot was used to integrate receiver operating curves and optimal cut-off for PSA in accordance with Bayesian theory. Results: Seventy percent of AA men and 52% of Hispanic men with hepatitis C antibody testing had Pca, while 68% of AA and 70% of Hispanic men with hepatitis C antibody detected had Pca. African American men had significantly higher rates of Pca, hepatitis C antibody detected, HIV, and higher cancer stage at diagnosis when compared to Hispanic men. Prostate cancer was more likely to metastasize despite average histological Gleason scores of less than 7 and was not related to number of cancer containing cores at biopsy. PSA did not meet criteria required of standard screening tests to detect Pca in this patient population. Conclusions: In New York City, African American and Hispanic men referred for prostate biopsy with a history of hepatitis C antibody detection or indication for testing have the highest rates of Pca detected in any group identified to date, with high rates of metastatic disease at presentation independent of PSA, histological Gleason scores and number of cores containing cancer at diagnostic biopsy. The presence of serum hepatitis C antibody significantly increases odds of Pca.

show abstract

Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration

Cited by 16 publications

References 26 publications

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

Hepatitis C virus as a systemic disease: reaching beyond the liver

Hepatitis C antibody testing in African American and Hispanic men in New York City with prostate biopsy

Contact Info

Product

Resources

About